Biora Therapeutics Unveils Revolutionary BioJet™ Device
Biora Therapeutics, Inc. (NASDAQ: BIOR), a leader in innovative drug delivery solutions, has some exciting news to share. The company's Chief Executive Officer, Adi Mohanty, is set to present their latest advancement—the 00-size BioJet™ device—at an upcoming event dedicated to drug delivery innovations.
About the Upcoming Presentation
At the anticipated 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, occurring soon, Mohanty will detail the remarkable work that has gone into perfecting the BioJet™ technology. This event will take place in a renowned venue where professionals from various sectors including pharma and biotech come together to discuss cutting-edge advancements.
Presentation Details
The presentation titled, "Solving Drug Delivery Challenges with Ingestible Drug-Device Combinations," promises to provide insights into the evolution of the BioJet device. Although the event will occur on October 28, 2024, the anticipation is building. With an earlier size of 000, the new version is designed to meet patient preferences while also promising improved payload capacity.
Why the BioJet Matters
The integration of the BioJet technology is a game-changer in drug delivery. Adi Mohanty expressed excitement about the reduction in size and enhanced usability of the device. This smaller capsule design is expected to resonate well with patients who prefer less invasive methods of treatment. The BioJet™ represents a leap forward in the delivery of liquid medications without the need for needles, which can often deter patients from adhering to treatment regimens.
Innovating Drug Delivery Technology
The industry is witnessing a transformation as companies like Biora Therapeutics leverage smart pill-based therapeutics platforms to address long-standing challenges in drug administration. The focus of the PODD meeting also includes discussions about various agent types, from peptides to small molecules, and how innovative delivery systems can enhance therapeutic outcomes.
About Biora Therapeutics
Biora Therapeutics is committed to advancing healthcare through innovation. The company's two primary platforms, NaviCap™ and BioJet™, are designed to enhance the efficacy of treatments while catering to patient comfort. The NaviCap™ platform, targeting colon treatment specifically for inflammatory bowel disease (IBD), is aimed at improving localized treatment without systemic side effects. Meanwhile, the BioJet™ platform supports the delivery of larger molecules orally, providing a much-needed alternative to traditional injections.
Company Contact Information
If you would like to learn more about Biora Therapeutics or the BioJet™ device, please reach out to:
Investor Contact:
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact:
Liz Robinson
CG Life
lrobinson@cglife.com
Frequently Asked Questions
What is the BioJet™ device?
The BioJet™ device is a new, needle-free injectable technology developed by Biora Therapeutics designed for improved patient comfort and enhanced drug delivery.
When will the presentation take place?
The presentation on the BioJet™ device will occur on October 28, 2024, during the PODD meeting.
What are the key benefits of the BioJet™?
The BioJet™ device allows for greater patient acceptance due to its smaller size and eliminates the need for needles, which can be painful and daunting for many patients.
Who will present at the PODD meeting?
Adi Mohanty, the CEO of Biora Therapeutics, will lead the presentation on the BioJet™ device.
How does Biora Therapeutics aim to improve treatment outcomes?
Biora Therapeutics focuses on developing bioengineered solutions that enhance drug delivery directly to the site of action, thus improving the efficacy of treatments while minimizing side effects.
